Filing Details
- Accession Number:
- 0001209191-20-035621
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-06-10 17:26:35
- Reporting Period:
- 2020-06-09
- Accepted Time:
- 2020-06-10 17:26:35
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1595893 | Turning Point Therapeutics Inc. | TPTX | Pharmaceutical Preparations (2834) | 463826166 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1772259 | Jean Jingrong Cui | C/O Turning Point Therapeutics, Inc. 10628 Science Center Drive, Ste. 200 San Diego CA 92121 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-06-09 | 412 | $63.80 | 549,471 | No | 4 | S | Indirect | By spouse |
Common Stock | Disposition | 2020-06-09 | 1,688 | $64.82 | 547,783 | No | 4 | S | Indirect | By spouse |
Common Stock | Disposition | 2020-06-09 | 4,515 | $65.80 | 543,268 | No | 4 | S | Indirect | By spouse |
Common Stock | Disposition | 2020-06-09 | 2,585 | $66.60 | 540,683 | No | 4 | S | Indirect | By spouse |
Common Stock | Disposition | 2020-06-09 | 300 | $67.48 | 540,383 | No | 4 | S | Indirect | By spouse |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By spouse |
No | 4 | S | Indirect | By spouse |
No | 4 | S | Indirect | By spouse |
No | 4 | S | Indirect | By spouse |
No | 4 | S | Indirect | By spouse |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 1,001,298 | Direct | |
Common Stock | 300,000 | Indirect | By The Jean Cui 2020 GRAT |
Footnotes
- Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li.
- The weighted average sale price for the transaction reported was $63.80, and the range of prices were between $63.25 and $64.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $64.82, and the range of prices were between $64.26 and $65.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $65.80, and the range of prices were between $65.26 and $66.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $66.60, and the range of prices were between $66.27 and $67.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $67.48, and the range of prices were between $67.34 and $67.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.